UBS has downgraded Ambev S.A. from 'Neutral' to 'Sell' due to a 3.78% year-over-year revenue decline, raising concerns about the beverage company's financial health. Currently trading at $3.29, Ambev's shares fell slightly by 0.15%, despite a 32% increase over the past six months. Analysts foresee a potential downturn with a price target of $3.04, while mixed investor sentiment continues, as evidenced by Seeking Alpha's 'Buy' rating. This follows a previous week when Ambev's stock spiked over 13% after a strong earnings report, despite challenges in market growth and rising costs.
Click a month on the chart to update the report below.
